Edition:
United Kingdom

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

1.64USD
23 May 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.64
Open
$1.62
Day's High
$1.74
Day's Low
$1.61
Volume
50,872
Avg. Vol
225,623
52-wk High
$8.37
52-wk Low
$0.65

Latest Key Developments (Source: Significant Developments)

vTv Therapeutics Q1 GAAP Loss Per Share $0.30
Tuesday, 15 May 2018 

May 15 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS.Q1 GAAP LOSS PER SHARE $0.30.Q1 EARNINGS PER SHARE VIEW $-0.34 -- THOMSON REUTERS I/B/E/S.  Full Article

Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL RECEIVE AN UPFRONT PAYMENT.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL ALSO RECEIVE SHARES OF RENEO PHARMACEUTICALS' COMMON STOCK.  Full Article

vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM.VTV THERAPEUTICS-GRANTED HUADONG PHARMACEUTICAL EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE GLP-1R AGONIST PROGRAM IN CHINA, HK, AND OTHER COUNTRIES.VTV THERAPEUTICS INC SAYS WILL RECEIVE AN $8 MILLION UPFRONT PAYMENT AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $75 MILLION IN MILESTONE PAYMENTS.  Full Article

VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING.VTV THERAPEUTICS INC - ENTERED AGREEMENT FOR INVESTOR'S COMMITMENT TO PURCHASE, CO'S CLASS A COMMON STOCK AT $4.38/SHARE.VTV THERAPEUTICS INC - AMOUNT OF COMMON STOCK THAT MAY BE PURCHASED BY INVESTOR PURSUANT TO LETTER AGREEMENT IS LIMITED TO $10.0 MILLION.  Full Article

vTv Therapeutics reports Q3 GAAP loss per share of $0.38
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Vtv Therapeutics Inc ::vTv Therapeutics reports third quarter 2017 financial and operational results.Q3 GAAP loss per share $0.38.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Qtrly ‍non-GAAP net loss per fully exchanged share was $0.38​.Research and development expenses were $9.0 million in Q3 of 2017, compared to $9.6 million in Q2 of 2017​.  Full Article

vtv Therapeutics completes enrollment of phase 2 trial evaluating TTP273 for treatment of type 2 diabetes
Tuesday, 16 Aug 2016 

vtv Therapeutics Inc : vtv therapeutics completes enrollment of phase 2 trial evaluating TTP273 for treatment of type 2 diabetes .Topline results are expected late this year.  Full Article

BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA

* VTV THERAPEUTICS ANNOUNCES COMPANY WILL PRE-SPECIFY NEW SUBGROUP WITH THE FDA AND REPORT PHASE 3 PART B RESULTS IN JUNE